Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin    LUPIN   INE326A01037

LUPIN (LUPIN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Lupin : Reports from Lupin, Ltd. Advance Knowledge in Central Nervous System Agents (Novel Process for Preparation of Tetrabenazine and Deutetrabenazine)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 10:28pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Fresh data on Drugs and Therapies - Central Nervous System Agents are presented in a new report. According to news originating from Maharashtra, India, by NewsRx correspondents, research stated, "A novel process for the synthesis of tetrabenazine (1) and deutetrabenazine (2), two well-known drugs used for the treatment of chorea associated with Huntington's disease, has been developed."

Our news journalists obtained a quote from the research from Lupin, Ltd., "All of the reaction parameters were optimized through a series of reactions and by using Design of Experiment techniques. The newly developed methods are industrially scalable and employ cheap, commercially available raw materials and hence are highly efficient."

According to the news editors, the research concluded: "The added advantage is that the developed processes evade the use of genotoxic alkylating agents and therefore could be considered as safe and viable alternatives to the existing methods."

For more information on this research see: Novel Process for Preparation of Tetrabenazine and Deutetrabenazine. Organic Process Research & Development, 2018;22(4):520-526. Organic Process Research & Development can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Organic Process Research & Development - www.pubs.acs.org/journal/oprdfk)

The news correspondents report that additional information may be obtained from P.C. Ray, Lupin Ltd., Lupin Res Pk, Pune 412115, Maharashtra, India. Additional authors for this research include Y.D. Pawar, D.T. Singare, T.N. Deshpande and G.P. Singh (see also Drugs and Therapies - Central Nervous System Agents).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.oprd.8b00011. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Maharashtra, India, Asia, Central Nervous System Agents, Health and Medicine, Drugs and Therapies, Tetrabenazine, Lupin Ltd., Business, Lupin, Ltd.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN
05/17LUPIN : Reports from Lupin, Ltd. Advance Knowledge in Central Nervous System Age..
AQ
05/15LUPIN LTD'S Q4FY18 CONSOLIDATED ADJU : Beats Estimates
AQ
05/14LUPIN : Nagpur plant completes successful USFDA inspection
AQ
05/10LUPIN : New Findings in Huntington Disease Described from Lupin, Ltd. [Bilateral..
AQ
05/07GLENMARK PHARMACEUTICALS : Mylan partnered indian firms to keep r&d costs low
AQ
04/23LUPIN : receives final approval to gXenazine
AQ
04/12LUPIN : Patent Issued for Process for Preparation of Levothyroxine and Salts (US..
AQ
04/07LUPIN : Gets eir from fda for pithampur facility
AQ
04/06LUPIN : Pithampur I unit clears inspection, warning letter remains on Pithampur ..
AQ
04/06LUPIN : Sensex ends higher; Lupin gains
AQ
More news
Financials ( INR)
Sales 2019 171 B
EBIT 2019 23 834 M
Net income 2019 16 700 M
Debt 2019 37 971 M
Yield 2019 0,92%
P/E ratio 2019 19,80
P/E ratio 2020 16,75
EV / Sales 2019 2,24x
EV / Sales 2020 2,00x
Capitalization 346 B
Chart LUPIN
Duration : Period :
Lupin Technical Analysis Chart | LUPIN | INE326A01037 | 4-Traders
Technical analysis trends LUPIN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 42
Average target price 846  INR
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Alok Ghosh President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN-16.19%5 073
JOHNSON & JOHNSON-11.08%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916